Bliss GVS Pharma Boosts Employee Ownership with 66,380 New Equity Shares Under ESOP

Bliss GVS Pharma Limited , a prominent player in the pharmaceutical sector, has taken a significant step to enhance employee engagement and align their interests with the company's growth. The company's ESOP Allotment Committee has approved the issuance of 66,380 new equity shares under its Employee Stock Option Plan (ESOP) 2019.

Key Details of the ESOP Allotment

Aspect	Details
Number of Shares Allotted	66,380
Face Value per Share	Re. 1.00
Exercise Price per Share	Rs. 43.00
Total Issued Share Capital After Allotment	10,57,88,972 shares
Total Issued Share Capital Value	Rs. 10,57,88,972.00
Lock-in Period for New Shares	6 months

This strategic move by Bliss GVS Pharma demonstrates its commitment to fostering a sense of ownership among its employees and aligning their interests with the company's long-term success.

Impact on Share Capital

The allotment has resulted in a marginal increase in the company's total issued share capital. Prior to this allotment, the company had 10,57,22,592 equity shares. The addition of 66,380 new shares represents an increase of approximately 0.63% in the total number of outstanding shares.

Financial Context

While the ESOP allotment itself doesn't directly impact the company's financial performance, it's worth noting some key financial metrics to provide context:

Metric	Value (in Rs. crore)	YoY Change
Total Assets	1,219.70	+6.03%
Shareholders' Capital	1,058.60	+7.10%
Reserve & Surplus	1,048.10	+7.18%

These figures indicate that Bliss GVS Pharma has been experiencing steady growth in its asset base and shareholder equity.

Conclusion

The recent ESOP allotment by Bliss GVS Pharma underscores the company's focus on employee retention and motivation. By offering equity ownership to eligible employees, the company aims to create a stronger sense of belonging and commitment among its workforce. This move aligns with modern corporate practices that emphasize the importance of employee engagement in driving long-term organizational success.

As the newly allotted shares come with a 6-month lock-in period, it ensures that the participating employees have a vested interest in the company's performance over the coming months. This alignment of interests between the employees and the company could potentially contribute to improved productivity and overall corporate performance.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.91%	+5.35%	+9.70%	+19.40%	+4.34%	-10.37%

Bliss GVS Pharma Limited, a prominent player in the pharmaceutical industry, announced a significant change in its leadership. The company's Managing Director, Gagan Harsh Sharma (DIN: 07939421), has resigned from his position, effective immediately from November 6, 2025.

Resignation Details

The Board of Directors of Bliss GVS Pharma Limited convened a meeting at the company's registered office on November 6, 2025, where they accepted Mr. Sharma's resignation. Mr. Sharma cited other professional commitments as the reason for his departure.

Impact on Company Positions

As a result of his resignation, Mr. Sharma will also step down from several key positions within the company:

Position	Committee
Member	Audit Committee
Member	Corporate Social Responsibility Committee
Member	Risk Management Committee

Additionally, Mr. Sharma has relinquished his directorship roles in the following subsidiary and associate companies:

Kremoint Pharma Pvt. Ltd.
Bliss GVS International Pte Ltd (Singapore)
Asterisk Life Sciences Ghana Ltd
EPII Exports Pvt. Ltd.
Asterisk Lifesciences GB Limited (UK)

Family Connections

Mr. Sharma has familial ties within the company's leadership:

Spouse of Dr. Vibha Sharma, Whole-Time Director
Brother-in-law of Mrs. Shruti Vishal Rao, also a Whole-Time Director

Other Board Decisions

In the same board meeting, which lasted from 4:30 PM to 6:10 PM, the company also:

Approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025
Appointed Mr. Shreekrushna Joshi as Head – Legal and Senior Management Personnel, effective from November 6, 2025

The company has informed the National Stock Exchange of India Ltd. and BSE Limited about these developments, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

As Bliss GVS Pharma Limited navigates this transition in leadership, stakeholders will be observing how these changes may impact the company's future direction and performance in the pharmaceutical sector.